Diabetic Neuropathy Clinical Trials 2024

Diabetic Neuropathy Clinical Trials 2024

Diabetic Neuropathy research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in diabetic neuropathy clinical trials today.

Diabetic Neuropathy Clinical Trials

Here are the 6 most popular medical studies for diabetic neuropathy

Popular filter options for diabetic neuropathy trials

Diabetic Neuropathy Clinical Trials With No Placebo

View 29 diabetic neuropathy medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to diabetic neuropathy

What are the top hospitals conducting diabetic neuropathy research?

In the realm of clinical trials for diabetic neuropathy, several hospitals are making strides in exploring innovative treatments and improving patients' quality of life. Truwell Health, located in Saint Petersburg, is one such institution that has dedicated its efforts to this condition. While currently conducting one active trial for diabetic neuropathy and having completed just a single trial thus far, their commitment to research and advancement is evident. In another part of Florida, the renowned medical facility Florida Pain management Associates, P.A., with locations both in Sebastian and Vero Beach, joins the ranks with equal enthusiasm. They too have initiated one ongoing clinical trial focused on diabetic neuropathy and have undertaken a sole previous study as well.

Further expanding this landscape is Centurion Spine and Pain Centers situated in Brunswick alongside Waycross—both contributing significantly to the understanding of diabetic neuropathy through their active engagement in current trials while also recording only a solitary completed study each since 2022 being their pioneering year.

Though these numbers may appear modest compared to larger institutions or more established fields within medical research, they highlight essential contributions made by these hospitals towards addressing an underrepresented aspect of diabetes-related complications. Diabetic neuropathy can cause debilitating pain and functional impairment for individuals affected by it; therefore any progress made through these clinical trials holds significant potential for alleviating suffering experienced by countless patients worldwide.

Which are the best cities for diabetic neuropathy clinical trials?

When it comes to clinical trials for diabetic neuropathy, several cities are emerging as frontrunners in research. Winston-Salem, North carolina; Hinsdale, Illinois; Miramar, Florida; Saint Louis, Missouri; and Baltimore, Maryland each have 2 active trials focused on finding effective treatments. These studies explore a range of interventions such as Axon Therapy + CMM and 10 kHz SCS plus CMM in Winston-Salem, Active tDCS + Active TUS in Hinsdale, Erchonia® EVRL™ in Miramar, Fish-oil derived n-3 polyunsaturated fatty acids in Saint Louis, and lifestyle modification approaches in Baltimore. By conducting these trials across multiple locations nationwide, researchers are working towards improving the lives of individuals with diabetic neuropathy through innovative therapies and strategies.

Which are the top treatments for diabetic neuropathy being explored in clinical trials?

Exciting advancements are taking place in clinical trials for the treatment of diabetic neuropathy. In particular, active transcranial direct current stimulation (tdcs) combined with active transcutaneous ultrasound (TUS), Erchonia® EVRL™ therapy, fish oil concentrate oral capsules, and fish-oil derived n-3 polyunsaturated fatty acids have emerged as top contenders. Each treatment is currently being explored in one active trial dedicated to diabetic neuropathy. These innovative therapies showcase promising potential and offer hope for improving the lives of those affected by this condition.

What are the most recent clinical trials for diabetic neuropathy?

Recent clinical trials for diabetic neuropathy offer hope and potential advancements in treatment. One noteworthy trial focuses on the use of eptinezumab, a drug that shows promise in addressing the symptoms of diabetic neuropathy. Additionally, fish oil concentrate in oral capsule form has undergone Phase 1 and Phase 2 trials to assess its efficacy in managing this condition. Another innovative approach involves combining active transcranial direct current stimulation (tdcs) with active transcutaneous ultrasound stimulation (TUS). This combination therapy is being studied to determine its effectiveness in alleviating symptoms associated with diabetic neuropathy. Lastly, naltrexone and pregabalin are also subjects of investigation as possible treatments for this challenging condition. With ongoing research into these various interventions, new possibilities may emerge that can improve the lives of individuals living with diabetic neuropathy.

What diabetic neuropathy clinical trials were recently completed?

In the realm of diabetic neuropathy, several recent clinical trials have reached completion, showcasing promising advancements in treatment options. Notably, Eli Lilly and Company concluded a trial for LY3526318 in January 2022, while Regenacy Pharmaceuticals LLC completed their ricolinostat study in December 2020. Additionally, WinSanTor Inc.'s topical solution Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) saw its trial come to an end in November 2020. These trials, along with others like ETX-018810 by Eliem Therapeutics and LY3016859 by Eli Lilly and Company, provide hope for individuals affected by diabetic neuropathy and signify significant progress towards improved care strategies.